Phio Pharmaceuticals to Present at H.C. Wainwright Conference
News related to:Phio Pharmaceuticals Corp · 2 min read
Phio Pharmaceuticals Corp, a clinical-stage biotechnology company, will participate in the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026, at the Lotte New York Palace Hotel in New York City. The company’s management team, including President and CEO Robert Bitterman and Chief Financial Officer Lisa Carson, will be available for one-on-one meetings with investors.
At the conference, Phio Pharmaceuticals will discuss its clinical lead candidate, PH-762, which is designed to silence the PD-1 gene implicated in various forms of skin cancer. PH-762 is part of the company’s INTASYL® siRNA gene-silencing technology, aimed at enhancing the body’s immune cells to more effectively kill cancer cells. The Phase 1b trial of PH-762, which evaluated its use in treating cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma, is ongoing.
According to the company, management will also address strategic priorities and upcoming initiatives designed to support continued execution and long-term value creation. Robert Bitterman, President and CEO, stated, “We are excited to present our progress and discuss our plans with investors at the H.C. Wainwright conference. PH-762 represents a significant step forward in our mission to develop innovative treatments for skin cancer.”
The webcast of Phio Pharmaceuticals’ presentation will be available through the link provided on the company’s website, www.phiopharma.com. The conference offers a platform for investors to gain insights into the company’s advancements and future directions.
Phio Pharmaceuticals’ lead clinical development program focuses on the potential of PH-762 as a non-surgical treatment for skin cancers. The company believes that PH-762 has the potential to revolutionize the treatment landscape for these conditions. As the conference progresses, investors and attendees will have the chance to learn more about the company’s strategic plans and the potential impact of PH-762 on the market.
The H.C. Wainwright 28th Annual Global Investment Conference brings together leading industry experts, investors, and analysts to discuss the latest trends and opportunities in the biotechnology sector. Phio Pharmaceuticals’ participation underscores the company’s commitment to advancing its technology and exploring new avenues for skin cancer treatment.